After the announcement made by the drug maker company has launched a novel anti-cancer drug, Palbociclib, in India for patients with advanced breast cancer. Sun Pharmaceutical Industries advanced 1.23% to Rs 1,024.05.
Palenotm (Palbociclib) is the brand name available under the medicine. Palbociclib is approved by the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA) and Central Drugs Standard Control Organisation (CDSCO) in combination with hormonal therapies for patients with hormone receptor-positive, human epidermal growth factor receptor two negative locally advanced or metastatic breast cancer.

Sun Pharma is India’s top pharmaceutical company and is the fourth-largest speciality generic pharmaceutical company.
On a consolidated basis, the net profit of pharma major hit a high at 10.51% to Rs 2,262.22 crore on 13.11%, revenue from operations up to Rs 10,809.19 crore in the July-September quarter of FY23 over the July-September quarter of FY22.